{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"28.3","value":"18.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"The duration of response as determined from IERC tumor assessment was calculated for each participant with a confirmed response (CR or PR) as the time from first observation of response until first observation of documented disease progression or death when death occurs within 12 weeks of the last tumor assessment, whichever occurs first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.","dispersionType":"Full Range","groups":[{"description":"Participants received Avelumab as first-line treatment for metastatic or distally recurrent MCC at a dose of 10 mg/kg as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.","id":"OG000","title":"Part B: Avelumab"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set included all participants who received at least 1 dose of study treatment. Here \"Number of participants analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 396 weeks","title":"Part B: Duration of Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1","type":"SECONDARY","unitOfMeasure":"Months"}